Vivos Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Vivos Therapeutics
VVOS Stock  USD 2.03  0.03  1.46%   
Vivos Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Vivos Therapeutics' valuation are provided below:
Gross Profit
9.7 M
Profit Margin
(0.99)
Market Capitalization
18.2 M
Enterprise Value Revenue
1.5971
Revenue
17.3 M
There are over one hundred nineteen available fundamental trend indicators for Vivos Therapeutics, which can be analyzed over time and compared to other ratios. All traders should double-check Vivos Therapeutics' current fundamentals against the performance from 2010 to 2026 and make sure the trends continue to evolve in the right direction. Market Cap is likely to drop to about 23.5 M in 2026. Enterprise Value is likely to drop to about 18.3 M in 2026

Vivos Therapeutics Total Revenue

14.14 Million

Check Vivos Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Vivos Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 0.0, Net Interest Income of 0.0 or Interest Income of 141.3 K, as well as many indicators such as Price To Sales Ratio of 1.57, Dividend Yield of 0.0 or PTB Ratio of 3.82. Vivos financial statements analysis is a perfect complement when working with Vivos Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Vivos Stock
Check out the analysis of Vivos Therapeutics Correlation against competitors.
For more information on how to buy Vivos Stock please use our How to Invest in Vivos Therapeutics guide.

Vivos Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets18 M17.6 M12.7 M
Slightly volatile
Short and Long Term Debt Total2.1 M1.7 M1.3 M
Slightly volatile
Other Current Liabilities2.1 M2.3 M1.4 M
Slightly volatile
Total Current Liabilities7.2 M5.7 M4.5 M
Slightly volatile
Other Liabilities774 K737.1 K269.3 K
Slightly volatile
Property Plant And Equipment Net3.1 M5 M2.3 M
Slightly volatile
Current Deferred Revenue766.1 K806.4 K1.4 M
Slightly volatile
Accounts Payable1.2 M1.3 M836 K
Slightly volatile
Cash8.7 M7.2 M4.8 M
Slightly volatile
Non Current Assets Total7.5 M9 M6.7 M
Slightly volatile
Non Currrent Assets Other184.7 K194.4 K238.9 K
Slightly volatile
Other Assets706.8 K409.4 K292.3 K
Slightly volatile
Long Term Debt379.2 K380.8 K472 K
Slightly volatile
Cash And Short Term Investments8.7 M7.2 M4.8 M
Slightly volatile
Net Receivables671.4 K387 K687.9 K
Very volatile
Good Will2.3 M2.6 M3.3 M
Slightly volatile
Common Stock Total Equity1.6 K2.1 K1.5 K
Slightly volatile
Common Stock Shares Outstanding6.1 M5.8 M1.5 M
Slightly volatile
Liabilities And Stockholders Equity18 M17.6 M12.7 M
Slightly volatile
Non Current Liabilities Total1.8 M2.7 M1.5 M
Slightly volatile
Other Current Assets872.4 K900.5 K506.9 K
Slightly volatile
Other Stockholder Equity72.4 M129 M47.1 M
Slightly volatile
Total Liabilities9 M8.4 M6 M
Slightly volatile
Net Invested Capital7.4 M7.2 M7.2 M
Pretty Stable
Property Plant And Equipment Gross4.4 M8.3 M3 M
Slightly volatile
Short and Long Term Debt1.7 M1.5 M835.1 K
Slightly volatile
Total Current Assets10.5 M8.6 M6 M
Slightly volatile
Short Term Debt407.8 K429.3 K615.6 K
Slightly volatile
Intangible Assets403.7 K333 K787.7 K
Slightly volatile
Common Stock1.9 K2.3 K1.5 K
Slightly volatile
Property Plant Equipment1.7 M3.2 M1.8 M
Slightly volatile

Vivos Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization535.3 K522.9 K625.1 K
Very volatile
Interest Expense1.4 M1.4 M442.9 K
Slightly volatile
Selling General Administrative21.5 M20.6 M14.9 M
Slightly volatile
Selling And Marketing Expenses3.3 M2 M2.1 M
Slightly volatile
Total Revenue14.1 M17.3 M8.9 M
Slightly volatile
Gross Profit9.7 M10.4 M6.1 M
Slightly volatile
Other Operating Expenses30.6 M30.1 M20.7 M
Slightly volatile
Cost Of Revenue4.4 M6.9 M2.8 M
Slightly volatile
Total Operating Expenses25.5 M23.2 M17.6 M
Slightly volatile
Reconciled Depreciation537.6 K522.9 K626.4 K
Very volatile
Research Development106.7 K90 K176.3 K
Slightly volatile

Vivos Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation651.5 K685.8 K1.4 M
Very volatile
Begin Period Cash Flow1.8 M1.9 M4.4 M
Pretty Stable
Depreciation535.3 K522.9 K625.1 K
Very volatile
Capital Expenditures980.2 K653.2 K1.1 M
Slightly volatile
Change To Operating Activities217.4 K180 K250.7 K
Slightly volatile
Issuance Of Capital Stock13.2 M9 M9.2 M
Slightly volatile
Total Cash From Financing Activities14.7 M20.6 M10.1 M
Slightly volatile
End Period Cash Flow8.7 M7.2 M4.8 M
Slightly volatile
Change To Netincome3.7 M4.4 M2.7 M
Slightly volatile
Change To Inventory240.4 K151.2 K318 K
Slightly volatile
Dividends Paid3 M3.3 M3.7 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio1.571.6516.0926
Slightly volatile
Days Sales Outstanding11.4112.0139.7241
Slightly volatile
Average Payables623 K700.9 K765 K
Slightly volatile
Stock Based Compensation To Revenue0.05540.05830.2308
Slightly volatile
Capex To Depreciation1.070.881.6296
Slightly volatile
EV To Sales1.221.2815.8123
Slightly volatile
Inventory Turnover8.39.3310.188
Slightly volatile
Days Of Inventory On Hand28.1531.6734.5724
Slightly volatile
Payables Turnover2.884.933.0135
Slightly volatile
Sales General And Administrative To Revenue1.771.371.9974
Slightly volatile
Research And Ddevelopement To Revenue0.01090.00830.0115
Slightly volatile
Capex To Revenue0.04130.04350.1984
Slightly volatile
Cash Per Share1.361.435.1699
Pretty Stable
Days Payables Outstanding12376.66133
Slightly volatile
Income Quality0.591.030.6983
Slightly volatile
Intangibles To Total Assets0.310.240.4298
Slightly volatile
Current Ratio1.141.351.1754
Pretty Stable
Receivables Turnover20.0131.4616.3245
Slightly volatile
Capex Per Share0.120.131.7489
Slightly volatile
Average Receivables620.5 K698 K761.9 K
Slightly volatile
Revenue Per Share3.273.4410.1816
Very volatile
Interest Debt Per Share0.330.351.8949
Pretty Stable
Debt To Assets0.180.110.1232
Pretty Stable
Operating Cycle11.4112.0141.7944
Slightly volatile
Days Of Payables Outstanding12376.66133
Slightly volatile
Ebt Per Ebit1.131.151.0335
Pretty Stable
Long Term Debt To Capitalization0.01260.01330.059
Slightly volatile
Total Debt To Capitalization0.170.180.4568
Pretty Stable
Quick Ratio1.141.351.1737
Pretty Stable
Net Income Per E B T1.111.151.0218
Slightly volatile
Cash Ratio0.941.130.8755
Slightly volatile
Days Of Inventory Outstanding28.1531.6734.5724
Slightly volatile
Days Of Sales Outstanding11.4112.0139.7241
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.21.04481.1696
Slightly volatile
Fixed Asset Turnover6.863.944.5952
Slightly volatile
Debt Ratio0.180.110.1232
Pretty Stable
Price Sales Ratio1.571.6516.0926
Slightly volatile
Asset Turnover0.740.890.6914
Slightly volatile
Gross Profit Margin0.760.690.7065
Pretty Stable

Vivos Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap23.5 M24.8 M73.9 M
Slightly volatile
Enterprise Value18.3 M19.3 M71.8 M
Slightly volatile

Vivos Fundamental Market Drivers

Vivos Upcoming Events

4th of April 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View
30th of September 2023
Last Quarter Report
View

About Vivos Therapeutics Financial Statements

Vivos Therapeutics shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Vivos Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Vivos Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Vivos Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue806.4 K766.1 K
Total Revenue17.3 M14.1 M
Cost Of Revenue6.9 M4.4 M
Stock Based Compensation To Revenue 0.06  0.06 
Sales General And Administrative To Revenue 1.37  1.77 
Research And Ddevelopement To Revenue 0.01  0.01 
Capex To Revenue 0.04  0.04 
Revenue Per Share 3.44  3.27 
Ebit Per Revenue(0.67)(0.70)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Vivos Stock Analysis

When running Vivos Therapeutics' price analysis, check to measure Vivos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vivos Therapeutics is operating at the current time. Most of Vivos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Vivos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vivos Therapeutics' price. Additionally, you may evaluate how the addition of Vivos Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY